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Abstract: Altered membrane permeability is a hallmark of inflammation and ischemia with 
systemic spreading. Renal dysfunction is a risk factor for cardiovascular, cerebrovascular, and 
metabolic diseases. The aim of the present study was to assess proteinuria and urinary polyclonal 
light chains in acute stroke and chronic cerebrovascular disease compared with other neurologic 
diseases. Our results showed significantly increased levels of urinary polyclonal light chains in 
cerebrovascular disease compared with other neurologic diseases. The highest values of urinary 
polyclonal κ chains were found in acute stroke compared with chronic cerebrovascular disease 
and other neurologic diseases, while the level of λ chains was mainly increased in chronic 
cerebrovascular diseases. The shift to chronic renal failure seems to be signaled by a decreased 
polyclonal light chain/creatinemia ratio. The absence of a significant correlation with blood 
pressure and other seric parameters suggests that polyclonal light chains are an early marker of 
reversible vascular impairment with renal dysfunction before progression to irreversible renal 
failure and need for dialysis and/or intensive care.
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Introduction
Altered membrane permeability is a hallmark of inflammation and incipient isch-
emia, as demonstrated by experimental, radiologic, and pathologic studies. Often, 
this is a   systemic condition, involving retinal, cerebral, cardiac, pulmonary, and renal 
vessels.
The presence of microalbuminuria is a risk factor both in the general population 
or in elderly people.1–3 Altered kidney function parameters further worsen the clinical 
course and prognosis of cardiovascular, cerebrovascular, and metabolic diseases.2–11 
They are associated with white matter lesions,12,13 silent brain infarction,14 a high preva-
lence of stroke,15,16 worse prognosis, in terms of both short- and long-term morbidity 
and mortality,9,10 and recurrence of vascular events (stroke, myocardial infarction, 
heart failure).10 Pathologic renal findings are also described in young patients affected 
with stroke, mainly related to hypertensive cardiopathy, nephroangiosclerosis, and 
chronic pyelonephritis.17 Lastly, renal dysfunction is related to cognitive impairment 
and dementia.18–21
Urinary polyclonal light chains are low to middle molecular weight proteins, filtered 
at the glomerular level and reabsorbed in the tubules by megalin-cubulin receptors.22–25 
In diabetes, the presence of polyclonal light chains is predictive of nephropathy in 
the absence of albuminuria.26 They herald systemic inflammation and progression of Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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renal injury to chronic renal failure.27 The aim of the present 
study was to evaluate proteinuria and urinary polyclonal light 
chains in acute and chronic cerebrovascular disease.
Materials and methods
Five-hundred and fifty patients came under our observation 
from August 2008 to February 2010, 36/553 (0.06%) of 
whom bounced back. They were recruited at the Department 
of Emergency and Assistance or through the Ambulatory 
Service. They or their family gave informed written consent 
at admission. The study was approved by the Institutional 
Review Board. All the patients underwent routine blood 
and urine examinations, and had an electrocardiogram and 
computed tomography within 24–48 hours. The diagnoses 
were acute stroke in 139 (58 males, mean age 75.01, standard 
deviation [SD] ± 10.85, 81 females, mean age 80.27 ± 9.04), 
Glasgow Coma Scale (GCS) 11.67 ± 2.94; chronic cerebral 
vascular disease in 361 (162 males, mean age 73.78 ± 10.33, 
199 females, mean age 77.61 ± 8.67), GCS 13.8 ± 2.03; and 
other neurologic diseases in 50 patients (23 males, mean age 
51.79 ± 4.24, 27 females, mean age 51.72 ± 20.43), GCS 
14.56 ± 1.61. Seventeen of 139 acute stroke cases (12%) 
were hemorrhagic. Blood pressure values were measured at 
admission by mercury sphygmomanometer.
Laboratory tests
Erythrocyte sedimentation rate was performed using standard 
vials. Serum parameters, ie, natremia, kalemia, glycemia, 
urea nitrogen, and creatinemia (Cre) were detected by Cobas 
Integra 800 Analyzer. C-reactive protein was measured by 
Dade Behring BN ProSpec Nephelometer. Urinary samples 
were treated with 0.1 M Hepes 0.1 M and 0.2 g/L sodium 
azide, then frozen and stored at -20°C. Proteinuria and uri-
nary light chains were analyzed by high-resolution agarose 
gel electrophoresis on Sebia Hydragel 2 IF and Hydragel 2 
Bence Jones immunofixation with anti-light chain antibodies 
and detection by a semiautomatic Hydrasis system. Some 
samples were analyzed by nephelometric immunoassay with 
specific anti-free light chain antibodies. The assay sensitiv-
ity was ,1 mg/L. Normal ranges for the studied parameters 
are reported in Table 1. Urinary tract infection and Bence 
Jones-positive samples were excluded from the statistical 
analysis.
statistical analysis
This was performed using the unpaired t-test, for standard 
description of baseline characteristics and differences 
among the study groups, and by Pearson correlation test 
and logarithmic regression analysis for identification of 
Table 1 Normal ranges for the studied parameters
  Normal values OND CCVD AS T test 
          AS vs OND AS vs CVD CCVD vs OND
Age (years)   51.11 ± 19.22 75.90 ± 9.61 78.52 ± 10.04 ns ns ns
gcs 15 14.56 ± 1.61 13.8 ± 2.03 11.67 ± 2.94 ns ns ns
sBP 120–129 mmhg 122.11 ± 16.66 137.13 ± 20.57 142.45 ± 23.71 ns ns ns
DBP 80–84 mmhg 78.17 ± 11.54 80.08 ± 11.18 82.17 ± 12.53 P 0.05 ns ns
MAP 93–96 mmhg 92.78 ± 12.15 99.12 ± 12.76 102.18 ± 14.7 ns ns P 0.002
Na 136–145 meq/L 138 ± 4.09 136.84 ± 4.87 137.5 ± 3.23 ns ns ns
K 3.30–5.1 meq/L 4.08 ± 0.45 4.14 ± 0.67 4.06 ± 0.57 ns ns ns
gly 70–110 mg/dL 90.42 ± 18.40 101.34 ± 36 111.25 ± 38.49 P 0.001 ns ns
UN 10–50 mg/dL 41.79 ± 23.54 48.55 ± 23.69 48.38 ± 24.08 P 0.03 ns ns
cre (males 0.7–1.2,  
females 0.5–0.9) mg/dL
0.83 ± 0.36 0.95 ± 0.45 0.95 ± 0.77 ns ns ns
esr 0–2 11.15 ± 12.16 20.85 ± 18.71 20 ± 26.9 P 0.005 ns P 0.004
crP 0–5 mg/L 11.35 ± 28.01 20.17 ± 12.16 19.62 ± 31.88 ns ns ns
UD 1005–1030 1017 ± 7.6 1015 ± 6.21 1018 ± 7.24 ns P 0.006 P 0.01
Proteinuria 0 17.81 ± 37.17 21.49 ± 44.31 19.62 ± 31.88 ns ns ns
Urinary κ chains 0–7.1 mg/L 11.34 ± 12.44 21.65 ± 29.41 24.16 ± 26 P 0.001 ns P 0.01
Urinary λ chains 0–3.9 mg/L 4.98 ± 4.27 11.97 ± 51.70 9.04 ± 9.19 P 0.004 ns P 0.02
PLc ratio 1–5 2.15 ± 0.74 2.47 ± 1.26 2.62 ± 1 P 0.056 ns ns
κ/cre ratio 0–5.9 0.17 ± 0.11 0.09 ± 0.02 0.42 ± 0.47 P 0.001 ns P 0.02
λ/cre ratio 0–3.25 0.06 ± 0.01 0.05 ± 0.02 0.12 ± 0.10 P 0.01 ns P 0.04
Abbreviations: As, acute stroke; ccVD, chronic cerebrovascular disease; cre, creatinemia; esr, erythrocyte sedimentation rate; crP, c-reactive protein; gcs, glasgow 
coma scale; gly, glycemia; K, kalemia; N, natremia; OND, other neurological diseases; PLc, polyclonal light chains; sD standard deviation; UD urinary density; UN, urea 
nitrogen; DBP, diastolic blood pressure; sBP, systolic blood pressure; MAP, mean arterial pressure.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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  association between the study parameters. P values , 0.05 
were   considered significant.
Results
Our data showed proteinuria in 116/149 (78%) acute stroke 
patients (26.85 ± 42.39 mg/dL), 265/384 (69%) chronic 
cerebrovascular disease patients (21.49 ± 40.74 mg/dL), 
and 35/53 (66%) patients with other neurologic diseases 
(17.81 ± 37.17 mg/dL, see Table 1). No statistically signifi-
cant difference was found between proteinuria in acute stroke, 
chronic cerebrovascular disease, and other neurologic dis-
eases. Urinary polyclonal light chains were mainly detected 
in cerebrovascular patients, with the highest significant levels 
of κ chains in acute stroke (24.16 ± 26 mg/L) compared with 
chronic cerebrovascular disease (21.65 ± 29.41 mg/L) and 
other neurologic diseases (11.34 ± 12.44 mg/L; acute stroke 
versus other neurologic diseases, P 0.001, and chronic cere-
brovascular disease versus other neurologic diseases, P 0.01. 
The level of λ chains was 9.04 ± 9.19 mg/L in acute stroke, 
11.97 ± 51.70 mg/L in chronic cerebrovascular disease, 
and 4.98 ± 4.27 mg/L in other neurologic diseases (acute 
stroke versus other neurologic diseases, P 0.004 and chronic 
cerebrovascular disease versus other neurologic diseases, 
P 0.02, Figure 1). A trend towards a difference in the urinary 
polyclonal light chain ratio was found between acute stroke 
and other neurologic diseases (acute stroke 2.62 ± 1.0, other 
neurologic diseases 2.15 ± 0.74, P 0.05). The polyclonal 
light chain/Cre ratio was increased in acute stroke (acute 
stroke κ/Cre 0.42 ± 0.47; acute stroke λ/Cre 0.12 ± 0.10), 
but was relatively decreased in chronic cerebrovascular 
disease (chronic cerebrovascular disease κ/Cre 0.09 ± 0.02; 
chronic cerebrovascular disease λ/Cre 0.05 ± 0.02) com-
pared with acute stroke and other neurologic diseases (other 
neurologic diseases κ/Cre 0.17 ± 0.11; other neurologic 
diseases λ/Cre 0.06 ± 0.01; and acute stroke κ/Cre versus 
other neurologic diseases κ/Cre, P 0.001; acute stroke κ/Cre 
versus chronic cerebrovascular disease κ/Cre, not statistically 
significant; chronic cerebrovascular disease κ/Cre ratio versus 
other neurologic diseases κ/Cre, P 0.02; acute stroke λ/Cre 
versus other neurologic diseases λ/Cre, P 0.01; acute stroke 
λ/Cre versus chronic cerebrovascular disease λ/Cre, not sta-
tistically significant; chronic cerebrovascular disease λ/Cre 
versus other neurologic diseases λ/Cre, P 0.04, Figure 2). At 
case history, hypertension was referred by 127/149 (85.23%) 
of acute stroke patients, 293/384 (76.3%) of patients with 
chronic cerebrovascular disease, 18/53 (34%) patients with 
other neurologic diseases, and diabetes was present in 29/149 
(19.46%) patients with acute stroke, 65/384 (16.92%) with 
chronic cerebrovascular disease, and 1/53 (0.01%) with other 
neurologic diseases. No significant correlation was found 
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Figure 1 Urinary PLcs in cerebrovascular dieseas (As, ccVD) compared to OND.
Abbreviations: PLcs, polyclonal light chains; OND, other neurological disease; As, acute stroke; ccVD, chronic cardiovascular disease.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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for proteinuria, urinary polyclonal light chains, systolic, 
diastolic, and mean arterial pressure values, and natremia, 
kalemia, glycemia, urea nitrogen, and creatinemia.
Conclusion
Our finding of a significant increase in urinary polyclonal light 
chains in acute and chronic vascular patients compared with 
those having other neurologic diseases, in the absence of a 
significant correlation with other systemic and renal param-
eters, suggests that urinary polyclonal light chains represent an 
early systemic marker of altered membrane permeability. The 
higher and more significant level of κ compared with λ chains 
in acute stroke can be explained by their higher physiologic 
production, up to twice the rate of λ.22 Their further increase 
in pathologic conditions is counterbalanced by augmented 
elimination and reduced reabsorption at the tubular level. Λ 
chains more frequently form dimers that slow their renal clear-
ance. We observed a relatively insignificant increase in urinary 
λ chains in chronic cerebrovascular disease compared with 
acute stroke. In tubular proteinuria, an increase of urinary low 
molecular weight proteins, as λ dimers, was detected. This is 
attributed to an increased excretion, a failure of proximal tubule 
reabsorption, and reduced catabolism.23 Unfolding intermedi-
ates are found after exposure to denaturing conditions, such as 
urea, heat, and pH variation.25 Higher seric concentrations of 
polyclonal light chains and a higher urinary polyclonal light 
chain/Cre ratio, together with increased glomerular filtra-
tion and reduced reabsorption at the tubular level have been 
reported.24,27 Serum and urinary concentrations of polyclonal 
light chains are related to the severity and progression of 
renal dysfunction.27 Taken together, our data suggest that the 
increase in urinary polyclonal light chains may be a negative 
prognostic sign and represent the boundary between a revers-
ible stage of renal dysfunction, namely nephrotic syndrome, in 
which there is still an opportunity for therapeutic intervention, 
and a definite progression to chronic kidney disease, indicated 
by a decreased polyclonal light chain/Cre ratio. This precedes 
an irreversible cascade of events characterized by reduction of 
glomerular filtration,27 systemic interstitial and parenchymal 
edema, infection, tubular necrosis, progression to uremia and 
irreversible renal failure, and need for emergency treatment, 
such as ventilatory assistance and hemodialysis. Therefore, it 
is important to prevent systemic complications that threaten 
the lives of patients, prolong hospitalization, cause frequent 
bounce-backs, diminish quality of life, and add further costs 
for sanitary assistance. The sensibility and specificity of such 
an assay for urinary polyclonal free light chains, their predic-
tive role concerning short- and long-term prognosis, and the 
association with cardiac and renal echographic and magnetic 
resonance imaging parameters are under evaluation.
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Figure 2 Urinary PLcs/cre ratio in cerebrovascular dieseas (As, ccVD) compared to OND.
Abbreviations: PLcs, polyclonal light chains; OND, other neurological disease; As, acute stroke; ccVD, chronic cardiovascular disease; cre, creatinemia.Neuropsychiatric Disease and Treatment
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